Clinical Trials
25 trialsNCT05386108 2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05768139 2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07038369 2026-06-03
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Phase 1 Active not recruiting
NCT04784715 2026-05-22
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT06993844 2026-05-06
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Phase 1/2 Recruiting
NCT04964934 2026-04-21
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
NCT05720039 2026-02-24
SP NSM
Intuitive Surgical
Phase NA Active not recruiting
NCT04711252 2025-10-14
SERENA-4
AstraZeneca
Phase 3 Active not recruiting
NCT06886659 2025-07-22
A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)
Incepta Pharmaceuticals Ltd
Phase 1 Completed
NCT04177108 2024-03-27
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03500380 2024-02-20
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
RemeGen Co., Ltd.
Phase 2/3 Unknown
NCT02422615 2023-11-30
MONALEESA-3
Novartis
Phase 3 Completed
NCT05792475 2023-11-27
Evaluation of TaiHao Breast Ultrasound Diagnosis Software RN-CES Descartes
TaiHao Medical Inc.
Phase NA Unknown
NCT04551105 2022-11-02
Evaluation of TaiHao Breast Ultrasound Diagnosis Software
TaiHao Medical Inc.
Phase NA Completed
NCT00039780 2022-07-13
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
NCT02897778 2022-04-28
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT02909452 2022-01-25
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT02820961 2021-12-15
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
Syndax Pharmaceuticals
Phase 1 Completed
NCT01594398 2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1 Completed
NCT00620594 2020-12-09
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT01743560 2019-07-18
4EVERUK
Novartis
Phase 4 Completed
NCT01204801 2015-09-24
Medifocus301
Medifocus, Inc.
Phase 3 Unknown
NCT00678626 2015-05-04
Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
Pfizer
Phase 2 Withdrawn
NCT00753415 2015-03-17
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00050427 2011-04-28
A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed